QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.109.152967v1 330/1/268    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Liu, J. J. Articles by Bostwick, J. R. PubMed PubMed Citation Articles by Liu, J. J. Articles by Bostwick, J. R.

NEUROPHARMACOLOGY

Discovery and Pharmacological Characterization of a Small-Molecule Antagonist at Neuromedin U Receptor NMUR2

AstraZeneca Pharmaceutical LLP, CNS/Pain HTS Center, Wilmington, Delaware (J.J.L., J.H., R.L., T.C., S.T., J.R.B.) and AstraZeneca R&D Montreal, Montréal, Quebec, Canada (K.P., M.C., J.M.A.L., C.-Q.C., J.B., S.L., M.B.)

Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception. By random screening of our corporate compound collection with a ligand binding assay, we discovered (R)-5'-(phenylaminocarbonylamino)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (R-PSOP), a highly potent and selective NMUR2 antagonist. R-PSOP is a nonpeptidic small-molecule with the chemical composition C₂₀N₄O₂H₂₂. In competition binding experiments, this compound was found to bind to NMUR2 with high affinity; the K_i values were determined to be 52 and 32 nM for the human and rat NMUR2, respectively. Moreover, in functional assays measuring phosphoinositide turnover or intracellular calcium mobilization, R-PSOP strongly inhibited the responses stimulated by peptide agonists NMU-25, NMU-23, and NMU-8 in human embryonic kidney 293 cells expressing NMUR2. From Schild analyses, the functional K_b values for R-PSOP were determined to be 92 and 155 nM at human and rat NMUR2, respectively. Highly selective for NMUR2, R-PSOP exhibited low affinity to the other subtype of NMU receptor, NMUR1, with a K_i value >10 µM. R-PSOP in vivo attenuated NMU-23-evoked nociceptive responses in a rat spinal reflex preparation. To our knowledge, this is the first antagonist ever reported for NMU receptors. This compound could serve as a valuable tool for further understanding the physiological and pathophysiological roles of NMU system, while providing a chemical starting point that may lead to development of new therapeutics for treatment of eating disorders, obesity, pain, and stress-related disorders.

Address correspondence to: Dr. Jay Liu, AstraZeneca Pharmaceutical LLP, CRDL C253H, 1800 Concord Pike, Wilmington, DE 19850-5437. E-mail: jay.liu{at}astrazeneca.com